β-cyclodextrin/epoxysuccinyl peptide conjugates:: new drug targeting system for tumor cells

被引：31
作者：
Schaschke, N
Assfalg-Machleidt, I
Machleidt, W
Lassleben, T
Sommerhoff, CP
Moroder, L [1 ]
机构：
[1] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[2] LMU Munchen, Adolf Butenandt Inst Physiol Chem Phys Biochem &, D-80336 Munich, Germany
[3] LMU Munchen, Klinikum, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany
[4] LMU Munchen, Klinikum, Chirurg Klin, D-80336 Munich, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2000年 / 10卷 / 07期
关键词：
D O I：
10.1016/S0960-894X(00)00078-0
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
beta-Cyclodextrin is known to form inclusion complexes with hydrophobic drugs. Several tumor cell lines are known to secrete and/or contain membrane-associated cathepsin B which is possibly involved in invasion and metastasis. Based on these informations. our recently developed endo-epoxysuccinyl peptide inhibitor MeO-Gly-Gly-Leu-(2S,3S)-tEps-Leu-Pro-OH for cathepsin B was conjugated with beta-cyclodextrin to obtain a site-directed drug carrier system. Furthermore, the conjugate was shown to form an inclusion complex with the cytotoxic drug methotrexate. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：677 / 680
页数：4
相关论文
共 14 条
  • [1] Cyclodextrin derivatives in pharmaceutics
    Albers, E
    Muller, BW
    [J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04): : 311 - 337
  • [2] RECOGNITION ABILITY AND CYTOTOXICITY OF SOME OLIGOSACCHARIDYL SUBSTITUTED BETA-CYCLODEXTRINS
    ATTIOUI, F
    ALOMAR, A
    LERAY, E
    PARROTLOPEZ, H
    FINANCE, C
    BONALY, R
    [J]. BIOLOGY OF THE CELL, 1994, 82 (2-3) : 161 - 167
  • [3] PYBOP - A NEW PEPTIDE COUPLING REAGENT DEVOID OF TOXIC BY-PRODUCT
    COSTE, J
    LENGUYEN, D
    CASTRO, B
    [J]. TETRAHEDRON LETTERS, 1990, 31 (02) : 205 - 208
  • [4] SYNTHESIS OF A NEW MOLECULAR CARRIER - N-(LEU-ENKEPHALIN)YL 6-AMIDO-6-DEOXY-CYCLOMALTOHEPTAOSE
    DJEDAINIPILARD, F
    DESALOS, J
    PERLY, B
    [J]. TETRAHEDRON LETTERS, 1993, 34 (15) : 2457 - 2460
  • [5] The cysteine protease cathepsin B in cancer
    Elliott, E
    Sloane, BF
    [J]. PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1996, 6 : 12 - 32
  • [6] FUJISHIMA A, 1997, FEBS LETT, V407, P761
  • [7] A NEW APPROACH TO ENHANCE BIOAVAILABILITY OF BIOLOGICALLY-ACTIVE PEPTIDES - CONJUGATION OF A DELTA-OPIOID AGONIST TO BETA-CYCLODEXTRIN
    HRISTOVAKAZMIERSKI, MK
    HORAN, P
    DAVIS, P
    YAMAMURA, HI
    KRAMER, T
    HORVATH, R
    KAZMIERSKI, WM
    PORRECA, F
    HRUBY, VJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (05) : 831 - 834
  • [8] THE REFINED 2.15-A X-RAY CRYSTAL-STRUCTURE OF HUMAN LIVER CATHEPSIN-B - THE STRUCTURAL BASIS FOR ITS SPECIFICITY
    MUSIL, D
    ZUCIC, D
    TURK, D
    ENGH, RA
    MAYR, I
    HUBER, R
    POPOVIC, T
    TURK, V
    TOWATARI, T
    KATUNUMA, N
    BODE, W
    [J]. EMBO JOURNAL, 1991, 10 (09) : 2321 - 2330
  • [9] Tumor protease-activated, pore-forming toxins from a combinatorial library
    Panchal, RG
    Cusack, E
    Cheley, S
    Bayley, H
    [J]. NATURE BIOTECHNOLOGY, 1996, 14 (07) : 852 - 856
  • [10] Cyclodextrin as carrier of peptide hormones.: Conformational and biological properties of β-cyclodextrin/gastrin constructs
    Schaschke, N
    Fiori, S
    Weyher, E
    Escrieut, C
    Fourmy, D
    Müller, G
    Moroder, L
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (28) : 7030 - 7038
12